Cypralis Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cypralis Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11046
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cypralis Ltd (Cypralis), formerly Selcia Pharma Ltd is a drug developer that provides discovery and development of therapeutics targeting peptidyl-prolyl isomerases. The company spans its expertise in the development of medicines for degenerative diseases such as acute tissue injury, liver disease, inflammation, and others. It develops pplases enzymes that are characterized by their ability to catalyze interconversion of cis- and trans- peptidyl-proline bonds in proteins that are able to exert control over target protein structure and functions. Cypralis works in partnership with pharma and biotech companies to develop ppiase inhibitors for acute and chronic diseases. The company operates in the UK. Cypralis is headquartered in Cambridge, the UK.

Cypralis Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cypralis Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Cypralis Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Cypralis Acquires Cyclophilin Inhibitor Assets from Scynexis 10
Partnerships 11
Cypralis Enters into Research Agreement with Janssen Pharma 11
Selcia Enters into Collaboration Agreement with Cypralis 12
Licensing Agreements 13
Cypralis Enters into Licensing Agreement with Gilead Sciences 13
Cypralis Ltd – Key Competitors 14
Cypralis Ltd – Key Employees 15
Cypralis Ltd – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Government and Public Interest 17
Mar 07, 2017: $4 Million in New Grants Support Several First-in-class Dementia Treatments 17
Mar 01, 2017: Cypralis Announces Grant Award from Alzheimer’s Drug Discovery Foundation 20
Product News 21
03/07/2017: Alzheimer’s Drug Discovery Foundation Awards $523,940 Million for Selective Cyclophilin D Inhibitors for Neurodegeneration 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Cypralis Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cypralis Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cypralis Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Cypralis Acquires Cyclophilin Inhibitor Assets from Scynexis 10
Cypralis Enters into Research Agreement with Janssen Pharma 11
Selcia Enters into Collaboration Agreement with Cypralis 12
Cypralis Enters into Licensing Agreement with Gilead Sciences 13
Cypralis Ltd, Key Competitors 14
Cypralis Ltd, Key Employees 15

List of Figures
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cypralis Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Cypralis Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Shangri-La Asia Ltd:企業の戦略・SWOT・財務情報
    Shangri-La Asia Ltd - Strategy, SWOT and Corporate Finance Report Summary Shangri-La Asia Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • New York Power Authority:電力:M&Aディール及び事業提携情報
    Summary New York Power Authority (NYPA) is a state-owned power organization. It generates electricity, and transmits and sells that on wholesale basis. The authority produces the electricity using hydro, gas, and oil sources. Through long-term electricity supply agreement with Astoria Energy II LLC, …
  • Achillion Pharmaceuticals Inc (ACHN):製薬・医療:M&Aディール及び事業提携情報
    Summary Achillion Pharmaceuticals Inc (Achillion) is a biopharmaceutical company which focuses on the discovery and development of small molecule therapeutic products for treatment of infectious diseases and immune system disorders. The company focuses at developing life-saving medicines to patients …
  • Pharmerica Corp:企業の戦略的SWOT分析
    Pharmerica Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Kia Motors Corporation:企業の戦略・SWOT・財務分析
    Kia Motors Corporation - Strategy, SWOT and Corporate Finance Report Summary Kia Motors Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Martifer SGPS SA (MAR):企業の財務・戦略的SWOT分析
    Martifer SGPS SA (MAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Swift Biosciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Swift Biosciences Inc (Swift Biosciences) is a biotechnology company that develops novel research reagents, protocols, and molecular diagnostic tools. The company offers products such as 2S DNA library kit, 2S plus DNA library kit, 2S PCR-free DNA library kit, methyl-seq DNA library kit, DNA …
  • HSH Nordbank AG:企業のM&A・事業提携・投資動向
    HSH Nordbank AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's HSH Nordbank AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Ameresco Inc (AMRC):企業の財務・戦略的SWOT分析
    Ameresco Inc (AMRC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Kineta Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Kineta Inc (Kineta) is a biotech company that develops novel immuno-therapies. The company offers small-molecule compounds that target RIG-I-like receptor pathways and intracellular IRF3-inducing pathways for applications in cancer. Its KCP-400 is a novel non-opioid therapy for the treatment …
  • Thin Film Electronics ASA (THIN):企業の財務・戦略的SWOT分析
    Thin Film Electronics ASA (THIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • PJSC MegaFon:企業のM&A・事業提携・投資動向
    PJSC MegaFon - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's PJSC MegaFon Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Fomento de Construcciones y Contratas SA (FCC)-エネルギー分野:企業M&A・提携分析
    Summary Fomento de Construcciones y Contratas SA (FCC) is a citizen services company. It manages and treats domestic and industrial waste; provides integrated water management services; and designs, develops and maintains infrastructure. The company provides engineering and construction services for …
  • Tallink Grupp AS:企業の戦略・SWOT・財務情報
    Tallink Grupp AS - Strategy, SWOT and Corporate Finance Report Summary Tallink Grupp AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • CAB Incorporated:企業の戦略的SWOT分析
    CAB Incorporated - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Deere & Company:企業の戦略・SWOT・財務情報
    Deere & Company - Strategy, SWOT and Corporate Finance Report Summary Deere & Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Chiyoda Corp (6366):企業の財務・戦略的SWOT分析
    Chiyoda Corp (6366) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Covea Insurance plc:企業の戦略・SWOT・財務情報
    Covea Insurance plc - Strategy, SWOT and Corporate Finance Report Summary Covea Insurance plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Singapore Power Ltd:企業の戦略的SWOT分析
    Singapore Power Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Genuine Parts Company (GPC):企業の財務・戦略的SWOT分析
    Genuine Parts Company (GPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆